Join Cook Children's health professionals as they present Doc Talk, a new podcast series keeping you on the edge of pediatric programs, research, life-changing treatments and the latest news that advances the care we provide to kids.
Beyond neuroscience research boundaries. Creating limitless possibilities.
Dr. Scott Perry, Medical Director of Neurosciences and Dr. Christos Papadelis, Director of Neurosciences Research along with Dianna Grado, Clinical Coordinator for Neurosciences Research, explore how breaking research boundaries creates limitless possibilities, paving the way for world-class research – and results once thought impossible for kids and young adults with neurological disorders.
Meet the speakers
Meet Dr. PerryMeet Dr. PapadelisDianna Grado, RN
Jane and John Justin Neurosciences Research Center
Adult Genetic Epilepsy Clinic
Comprehensive Epilepsy Program
Movement Disorders Clinic
Cerebral Palsy Clinic
Cook Children’s Neurology
Cook Children’s Neurosciences Research Center
Dodson Neuro Research Endowment
Primary steps for primary care: Sleep disorders in epilepsy and cerebral palsy
Infantile Spasms- Primary Steps for Primary Care
Staring Spells – Primary Steps for Primary Care
Febrile Seizures – Primary Steps for Primary Care
The Arcuate – Neuroscience Research
Early Identification and Improving Life-Long Outcomes in Cerebral Palsy Patients
New-Onset Seizure Clinic Seeks to Decrease Wait Time for Initial Evaluation
BE FAST to Recognize the Signs of Pediatric Stroke
Pioneering Surgery Disconnects Left Side of Brain to Stop Child’s Daily Seizures
Teen Becomes First in North Texas to Undergo Landmark Brain Surgery for Epilepsy
Host: Hello and welcome to this edition of Doc Talk. We're honored and excited today to be speaking with key researchers at Cook Children's Jane and John Justin Neurosciences Center. We're joined by Dr. Scott Perry, Medical Director of N
As pediatric congenital heart patients age out, where do they go?
With the growing number of pediatric congenital heart patients growing up thanks to ever improving medical care, Dr. Scott Pilgrim takes us inside one of the few programs in the nation that bridges the gap to adult care without missing a beat.
Meet the speaker
Meet Dr. Pilgrim
Cook Children's Adult Congenital Heart Disease Program
Adult Congenital Heart Disease Conditions
Cook Children's Heart Center Specialty Programs
Cook Children’s Heart Center
Coming home: nurse returns to Cook Children’s for open heart surgery
Diving heart first
Heart-to-heart. Mother and daughter share the same cardiologist
Hello and welcome to Cook Children's Doc Talk. Today we're talking with Dr. Scott Pilgrim, who is the medical director of the Adult Congenital Heart Disease program here at Cook Children's. Dr. Pilgrim is board-certified in pediatrics, internal medicine, pediatric cardiology and adult congenital cardiology. Prior to coming to Cook Children's, Dr. Pilgrim founded the adult congenital heart disease program at the Steven and Alexandra Cohen Children's Medical Center in Long Island. Today, under his leadership, the Adult Congenital Heart Disease program at Cook Children's Medical Center has shown tremendous growth with over 500 adult visits every year. Welcome Dr. Pilgrim.
So growing up with a sister who had heart surgery as a child had a major influence in your life, and ultimately led you to your role here at Cook Children's as medical director of the ACHD program, compared to many other cardiac specialties, adult congenital as a specialty is relatively new, can you give us a little history.
So, as you mentioned, my sister was born with a congenital heart disease. And so growing up with this in my family, it became of interest to me at a very young age. But as a field, congenital heart disease is something that has been around obviously, for several decades, this field of adult congenital heart disease has grown primarily because of the success stories that we've had in pediatric cardiology, namely, the surgical outcomes and the longevity of patients related to improved surgical care, improved surgical technique, you know, recognizing disease, early on fetal diagnosis, and so on and so forth. And so the incidence of congenital heart disease really hasn't changed. But the lifespan of individuals growing up with congenital heart disease has tremendously improved. And so when we think about the growth of adult congenital heart disease in the country, it really has grown out of necessity, because these kids are now growing up and becoming adults. In fact, the number of adults with congenital heart disease now far outweighs the number of children with congenital heart disease in th
Talking Cellular Immunotherapy, CAR T-Cell Therapy and Eradicating Pediatric Cancer
Dr. Holly Pacenta, Pacenta takes us into the future of curing and treating pediatric cancer through the use of the patient's own immune system to target the cancer. At the forefront of the technology is CAR T-cell therapy targeting relapsed and refractory B-ALL cells to eradicate cancer with minimal side effects.
Meet the speaker
Meet Dr. Pacenta
Cook Children's Cellular Immunotherapy program
Cook Children’s Leukemia and Lymphoma care
Cook Children's Oncology program
Cook Children's Hematology and Oncology
Host: Hello and welcome to Cook Children's Doc Talk. Our guest for this episode is pediatric hematologist oncologist Dr. Holly Pacenta. Dr. Pacenta began her career at Children's Hospital Colorado, where she developed her primary interest in new treatments for children with relapsed leukemia, including immunotherapy, cellular therapy and targeted therapy. She has been heavily involved in research, has published several works and received awards and recognition for her work. Today, Dr. Pacenta oversees the Cellular Immunotherapy program at Cook Children's where she and the oncology team are very excited about providing CAR T-cell therapy to patients with relapsed B-cell acute lymphoblastic leukemia, or ALL. Cellular immunotherapy introduces a new era in the treatment of children and young adults here at Cook Children's. Welcome Dr. Pacenta. We are very excited to have you here to talk about this incredible program and CAR T-cell therapy.
Dr. Pacenta: Thank you so much for having me.
Host: Can you start by giving us a little background on the cellular immunotherapy program and an overview of immunotherapy and CAR T-cell therapy?
Dr. Pacenta Sure. So I think first to give an overview of immunotherapy and CAR T-cell therapy, we think at the forefront of the future of curing and treating pediatric cancer is to use, help use the patient's own immune system to target the cancer. So that's what immunotherapy is. Immuno meaning the immune system in therapy meeting treatments, so using the immune system to help treat your own cancer. And then CAR T-cell is a form, kind of a hybrid, of cellular immunotherapy. So we use one of the cells as part of the immune system, the T cells that typically help fight infection, and those get sent to a lab where they're reprogrammed to target the leukemia. So that's CAR T-cell therapy is. Then, our cellular immunotherapy program is a dedicated group of oncologists and stem cell transplant doctors here at Cook Children's along with some supportive services like pharmacy, dieticians, psychologists, etc., that will help provide these types of therapies to our patients.
Host: So KYMRIAH® is the CAR T-cell therapy currently approved for pediatric treatment of children and young adults with refractory or relapsed B-cell ALL, why this particular condition?
Dr. Pacenta: Immunotherapy and cellular therapy are a big interest in pediatric cancer in general. And there has b
Heart Attack Prevention Begins in Early Childhood
Preventing adult heart attacks in early childhood? Don Wilson, M.D., explains why it's absolutely within REACH. Children with high cholesterol, especially those who have a genetic cause, such as familial hypercholesterolemia, also know as fH, are at a higher risk for developing premature heart disease, such as heart attack or stroke as they become adults. At the forefront of developing guidelines for lowering this risk, Dr. Wilson details how the Risk Evaluation to Achieve Cardiovascular Heath, or REACH, clinic at Cook Children's is putting those guidelines to work and changing the outcomes for these in the future, and saving the lives of parents today.
Meet the speaker
Dr. Don Wilson
Related InformationRisk Evaluation to Achieve Cardiovascular Health (REACH) Clinic
They're Active, Eat Healthy, and Have High Cholesterol-Why?
Kids at Risk of Smoke Exposure in Smoke-Free Areas?
A Simple Blood Test Could Save Your Child's Life
The Unique Risks of Being a Woman with Diabetes
Number of Children and Adolescents Who are Obese 10 Times Higher than 40 Years Ago
Host: Hello, and welcome to Cook Children's Doc Talk. Today we're talking with Dr. Don Wilson about genetic dyslipidemia, and cardiovascular disease. But first, here's just a little about Dr. Wilson. He is board certified in pediatrics, pediatric endocrinology and clinical lipidology. He is the founder and currently the medical director of Cook Children's REACH program, one of the first cardiovascular risk assessment clinics for children and adolescents in the nation. Dr. Wilson is a fellow of the National Lipid Association and an associate editor for The Journal of Clinical Lipidology and a member of the
Endoscopic Corpus Callosotomy: Breaking Boundaries to Stop a Child’s Daily Seizures
Neurosurgeon, Daniel Hansen, M.D. shines a light on this barrier breaking approach to epilepsy surgery. Using an endoscopic method to disconnect the left and right brain, this minimally invasive procedure has the same chance of seizure freedom post-surgery as traditional callosotomy, while reducing operating time and recovery time.
Meet the speaker
Meet Dr. Hansen
Pioneering Surgery Disconnects Left Side of Brain To Stop Child’s Daily Seizures
Boy Receives Pioneering Surgery to Stop Child's Daily Seizures
The Pioneer: Child Becomes First Patient in Trailblazing Endoscopic Surgery that Disconnects Part of His Brain to Stop Daily Seizures
Cook Children's Patient Becomes First in North Texas Implanted with Smart Device to Control Seizures
Teen with Cancer Walks a Marathon During Hospital Stays
Cook Children's Neurosurgery
Cook Children's Neonatal Neurology and Neurosurgery
Comprehensive Epilepsy Program
Jane and John Justin Neurosciences Center
Host: Hello and welcome to Cook Children's Doc Talk. Our guest for this episode is pediatric neurosurgeon Dr. Daniel Hansen. Dr. Hansen sees and treats children for the whole range of pediatric neurosurgical issues, and has special interest in minimally invasive surgery, endoscopic surgery, tumors and epilepsy. He works closely with the neuro-oncology and epileptology teams to provide cutting edge patient-centered treatment, using the most up to date information and treatment options. Dr. Hansen is the first neurosurgeon at Cook Children's and one of only two in the state of Texas to perform an endoscopic corpus callosotomy and endoscopic surgery on the corpus callosum that separates the right and left sides of the brain for children with certain types of intractable epilepsy or severe seizures. He's also one of the first pediatric surgeons in the nation to perform the endoscopic approach. Welcome, Dr. Hansen.
Dr. Hansen: Thank you.
Host: I want to sta
New Dimensions in Pediatric Heart Surgery
Listen NowDr. Steve Muyskens, Medical Director, Cardiac MRI, 3-D aPPROaCH Lab, Cook Children's, takes us into the world of 3D heart printing. It’s a fascinating journey into how this advancing technology can take the guess work out of pediatric heart surgery, helping more young patients can thrive into adulthood.
Dr. Steve Muyskens
Related InformationCook Children's 3D aPPROaCH LabCardiac Magnetic Resonance ImagingCook Children's Cardiothoracic Surgery programCook Children's Endowed Chair ProgramCook Children's Heart Center
Host: Hello and welcome to Cook Children's Doc Talk. Today we welcome Dr. Steve Muyskens, medical director of the Cardiac MRI program here at Cook Children's in Fort Worth, Texas. Dr. Muyskens, is an endowed chair supporting the expansion of our CMRI program and its diagnostic uses. He has since established the three-dimensional lab for the planning and printing of congenital heart disease, which uses advanced technology to support presurgical planning and family education for patients with complex heart conditions. He is our expert on this subject. So thank you for being with us today, Dr. Muyskens/
Dr. Muyskens: Thank you very much for the invitation.
Host: So what exactly is a 3D model? And what is the process for creating that model?
Dr. Muyskens So I think the important part is to kind of start with the patient. There are conditions with varying degrees of complexity that our current diagnostic modalities fall short in some manner. So those patients have long been difficult to manage. We started realizing that we can use technology like 3D printing and virtual 3D animation to help us better understand their condition. So when we identify that patient, whether it be an older patient who has already had some surgeries, or a newborn who has a very complex heart, who we're hoping to do an initial palliation, or surgical repair on, the first thing we decide is, what is the best modality to obtain the information that we would need to then use that technology. The two most commonly used technologies would be MRI, or cardiac CT. You can use rotational angiography in the cath lab, but that's much less commonly used. Once we have that selection made, the data is obtained by us obtaining a typical CT scan or a typical cardiac MRI. But then that data, which is in a raw form called DICOM. DICOM data is then moved to specialized software. And from there, I take that data, and we segment it is the term we use, basically manipulate that data and create a virtual model, essentially, from that information. That model can then be viewed either in the virtual space, so on a typical computer that you would flip around, but then again, you're still only in two dimensions you're looking at in a screen. So then typically, we move on to a 3D printing of that data. So the typical segmentation portion, or manipulation of the data, can vary from anywhere to two to 24 hours of time, depending on the complexity of the model. An